CTY SEC Filings, Earnings & Splits

A Schedule 13G was filed regarding City Therapeutics, Inc. (CTY), indicating a passive ownership position by an institutional or other holder. The filing directory does not disclose specific ownership percentages or holder identity in the provided text.

Arch Venture Fund XII, L.P. and affiliated reporting persons filed a Schedule 13D joint filing agreement regarding their beneficial ownership of City Therapeutics, Inc. stock.

Viking Global Investors LP and affiliated entities, along with O. Andreas Halvorsen and Rose S. Shabet, filed a joint filing agreement as an exhibit to a Schedule 13G regarding their position in City Therapeutics, Inc. The agreement allows the parties to jointly file required SEC ownership filings.

A joint filing agreement was filed under Schedule 13G by a group of affiliated entities and Raymond Debbane regarding their beneficial ownership of City Therapeutics, Inc. securities. The agreement allows the group to file ownership statements jointly under Rule 13d-1(k).

City Therapeutics, Inc. filed a Form 8-K cover page with no substantive event disclosure beyond routine registrant identification information.